Study Summary
This trial will test whether Noom, a weight-loss app, helps people with type 2 diabetes better stick to their exercise and diet plan, leading to more weight loss and better health.
Eligible Conditions
- Metabolic Syndrome
- Type 2 Diabetes
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: Over the course of 5 months
Month 5
Body Weight
Month 5
Flow-mediated dilation
Glucose Tolerance
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Exercise and Diet Standard of Care
1 of 2
Noom+Exercise and Diet Standard of Care
1 of 2
Active Control
Experimental Treatment
63 Total Participants · 2 Treatment Groups
Primary Treatment: Exercise and nutrition · No Placebo Group · N/A
Noom+Exercise and Diet Standard of CareExperimental Group · 2 Interventions: Exercise and nutrition, Noom mobile application · Intervention Types: Behavioral, Behavioral
Exercise and Diet Standard of Care
Behavioral
ActiveComparator Group · 1 Intervention: Exercise and nutrition · Intervention Types: BehavioralTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: over the course of 5 months
Who is running the clinical trial?
Rutgers, The State University of New JerseyLead Sponsor
374 Previous Clinical Trials
58,485 Total Patients Enrolled
1 Trials studying Metabolic Syndrome
80 Patients Enrolled for Metabolic Syndrome
Noom Inc.Industry Sponsor
15 Previous Clinical Trials
2,399 Total Patients Enrolled
Steven K Malin, PhDPrincipal InvestigatorRutgers University - New Brunswick
2 Previous Clinical Trials
160 Total Patients Enrolled
2 Trials studying Metabolic Syndrome
160 Patients Enrolled for Metabolic Syndrome
Eligibility Criteria
Age 30 - 70 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:A person with a body mass index between 28-45 kg/m2 is considered overweight.
A person who was previously diagnosed with T2DM.
People who are currently taking medications that affect heart rate and rhythm, such as calcium channel blockers, nitrates, alpha- or beta-blockers.
People aged 30 to 70 who are male or female.
Who else is applying?
What state do they live in?
| New York | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments